TrialCritical care (London, England)2023

The immunomodulating activity of trimodulin (polyvalent IgM, IgA, IgG solution): a post hoc analysis of the phase II CIGMA trial.

Mervyn Singer et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.